Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)
Close on Nov 13, 2026Market cap $7.92BP/E –Yield –
Rhythm Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Rhythm Pharmaceuticals's cash was $330.90M at Jun 30, 2026. For fiscal 2025 it was $388.90M, up 21.3% from the year before. Over ten years it grew 27.2% a year on average. The highest annual figure on record is $388.90M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $388.90M | +21.3% |
| FY2024 | Dec 31, 2024 | $320.60M | +16.2% |
| FY2023 | Dec 31, 2023 | $275.85M | -17.2% |
| FY2022 | Dec 31, 2022 | $333.29M | +13.0% |
| FY2021 | Dec 31, 2021 | $294.86M | +70.6% |
| FY2020 | Dec 31, 2020 | $172.79M | -40.9% |
| FY2019 | Dec 31, 2019 | $292.46M | +16.0% |
| FY2018 | Dec 31, 2018 | $252.06M | +70.2% |
| FY2017 | Dec 31, 2017 | $148.08M | +1305.4% |
| FY2016 | Dec 31, 2016 | $10.54M | -70.0% |
| FY2015 | Dec 31, 2015 | $35.09M | +22988.2% |
| FY2014 | Dec 31, 2014 | $152.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $330.90M | +13.7% |
| Q1 FY2026 | Mar 31, 2026 | $340.60M | +8.3% |
| Q4 FY2025 | Dec 31, 2025 | $388.90M | +21.3% |
| Q3 FY2025 | Sep 30, 2025 | $416.10M | +39.4% |
| Q2 FY2025 | Jun 30, 2025 | $291.00M | -8.8% |
| Q1 FY2025 | Mar 31, 2025 | $314.49M | +56.3% |
| Q4 FY2024 | Dec 31, 2024 | $320.60M | +16.2% |
| Q3 FY2024 | Sep 30, 2024 | $298.39M | -0.3% |
| Q2 FY2024 | Jun 30, 2024 | $319.13M | +25.8% |
| Q1 FY2024 | Mar 31, 2024 | $201.20M | -31.7% |
| Q4 FY2023 | Dec 31, 2023 | $275.85M | -17.2% |
| Q3 FY2023 | Sep 30, 2023 | $299.26M | -14.0% |
| Q2 FY2023 | Jun 30, 2023 | $253.60M | +7.6% |
| Q1 FY2023 | Mar 31, 2023 | $294.58M | +22.3% |
| Q4 FY2022 | Dec 31, 2022 | $333.29M | +13.0% |
| Q3 FY2022 | Sep 30, 2022 | $347.80M | +5.9% |
| Q2 FY2022 | Jun 30, 2022 | $235.60M | -36.0% |
| Q1 FY2022 | Mar 31, 2022 | $240.96M | -40.5% |
| Q4 FY2021 | Dec 31, 2021 | $294.86M | +70.6% |
| Q3 FY2021 | Sep 30, 2021 | $328.35M | +62.7% |
| Q2 FY2021 | Jun 30, 2021 | $368.15M | +61.0% |
| Q1 FY2021 | Mar 31, 2021 | $404.75M | +57.2% |
| Q4 FY2020 | Dec 31, 2020 | $172.79M | -40.9% |
| Q3 FY2020 | Sep 30, 2020 | $201.78M | +24.2% |
| Q2 FY2020 | Jun 30, 2020 | $228.63M | +17.1% |
| Q1 FY2020 | Mar 31, 2020 | $257.42M | +16.2% |
| Q4 FY2019 | Dec 31, 2019 | $292.46M | +16.0% |
| Q3 FY2019 | Sep 30, 2019 | $162.44M | -40.4% |
| Q2 FY2019 | Jun 30, 2019 | $195.17M | -32.1% |
| Q1 FY2019 | Mar 31, 2019 | $221.52M | +62.3% |
| Q4 FY2018 | Dec 31, 2018 | $252.06M | +70.2% |
| Q3 FY2018 | Sep 30, 2018 | $272.39M | +795.6% |
| Q2 FY2018 | Jun 30, 2018 | $287.55M | +3113.6% |
| Q1 FY2018 | Mar 31, 2018 | $136.45M | -7.9% |
| Q4 FY2017 | Dec 31, 2017 | $148.08M | +1305.4% |
| Q3 FY2017 | Sep 30, 2017 | $30.42M | +141.1% |
| Q2 FY2017 | Jun 30, 2017 | $8.95M | – |
| Q1 FY2017 | Mar 31, 2017 | $148.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.62M | – |
See a number that looks wrong?